

EHA 2020: Therapeutic developments in ALL, NHL, and MM

Faculty

Dr John P. Leonard, MD, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA

Dr Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Dr Noopur Raje, MD, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Release date: September 15, 2020

Expiration date: September 14, 2021

Estimated time to complete activity: 1.0 hours

Available CME Credits: 1 AMA PRA Category 1 Credit(s)[™]

Activity description

This activity will focus on educating HCPs involved in the care of patients with either acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), or multiple myeloma (MM) via a roundtable webcast featuring an expert discussion of new and exciting data presented at the EHA 2020 Annual Meeting. The renowned faculty will evaluate key and emerging data, and provide an expert commentary on the relevance and implications for clinical practice in each indication.

Target audience

This activity is intended for hematologists, oncologists, pathologists, and other HCPs involved in the care of patients with ALL, NHL, or MM.

Educational objectives

After completing this activity, the participant should be better able to:

- Recognize and describe the mechanisms of action of novel and emerging treatments for the management of hematologic malignancies (including ALL, NHL, and MM) as presented at the EHA 2020 Annual Meeting
- Examine and discuss the latest clinical trial data (efficacy, safety, tolerability) for the diagnosis and treatment of hematologic malignancies (including ALL, NHL, and MM) as presented at EHA 2020 Annual Meeting
- Develop and apply data-driven strategies to improve treatment selections and manage treatment-related toxicities in patients with ALL, NHL, and MM based on the review of the data presented at EHA 2020 Annual Meeting

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education.

Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity. In order to claim credit, participants must complete the following procedures during the period September 15, 2020 through September 14, 2021:

1. Read the educational objectives, accreditation information, and faculty disclosures
2. Take the pre-activity test
3. View the webcast
4. Take the post-activity test and complete the evaluation
5. Download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Dr John P. Leonard, MD	Consultant for ABC Therapeutics, AstraZeneca, Bayer, Bristol Myers Squibb/Celgene, Epizyme, Genmab, Gilead, Karyopharm Therapeutics, MEI Pharma, Miltenyi Biotec, Regeneron Pharmaceuticals, Sutro Biopharma.
Dr Daniel J. DeAngelo, MD, PhD	Consultant for Amgen, Autolus Therapeutics, Blueprint Medicines, Bristol Myers Squibb/Celgene, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Shire, and Takeda; and contracted researcher for AbbVie, Blueprint Medicines, Glycomimetics, and Novartis.
Dr Noopur Raje, MD	Consultant for Amgen, Bristol Myers Squibb, Caribou Biosciences, Immuneel Therapeutics, Janssen, Karyopharm Therapeutics, and Takeda; and contracted researcher for bluebird bio.

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by educational funding provided by Amgen.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Media

Internet